Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 31, 2009, Pages 3982-3990

  Roche, Sandra ^a   McMahon, Gillian ^a   Clynes, Martin ^a   O'Connor, Robert ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Dasatinib; Lapatinib; Liquid chromatography mass spectrometry; Liquid liquid extraction; Tyrosine kinase inhibitor

Indexed keywords

AMMONIUM FORMATE; CANCER CELLS; CANCER DRUG; CELLULAR LEVELS; ELECTROSPRAYS; ERLOTINIB; GEFITINIB; HIGHLY SENSITIVE; IMATINIB; IN-CELL; IONISATION; ISOCRATIC ELUTION; LAPATINIB; LC-MS/MS; LIMIT OF DETECTION; LIMIT OF QUANTIFICATIONS; LINE MODELS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; MEMBRANE PROTEINS; MOBILE PHASE; MONITORING MODE; OVER-EXPRESSION; P-GLYCOPROTEIN; SELECTIVE LIQUID CHROMATOGRAPHY; SORAFENIB; SPECTROMETRIC METHODS; TERT-BUTYL METHYL ETHERS; TRIPLE-QUADRUPOLE MASS SPECTROMETER; TYROSINE KINASE INHIBITOR; VALIDATION STUDY;

ACETONITRILE; AMINO ACIDS; AMMONIUM COMPOUNDS; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; ELECTROSPRAY IONIZATION; ETHERS; GLYCOPROTEINS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY; SOLVENT EXTRACTION;

LIQUIDS;

ACETONITRILE; AMMONIUM FORMATE; DASATINIB; ERLOTINIB; GEFITINIB; IMATINIB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TERT BUTYL METHYL ETHER;

ACCURACY; ARTICLE; CELL LEVEL; DRUG DETERMINATION; ELECTROSPRAY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIMIT OF DETECTION; MASS SPECTROMETRY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINAZOLINES; SENSITIVITY AND SPECIFICITY; THIAZOLES;

EID: 72049095884     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.10.008     Document Type: Article

References (28)

1. Steeghs N., Nortier J.W., and Gelderblom H. Ann. Surg. Oncol. 14 (2007) 942
2. Arora A., and Scholar E.M. J. Pharmacol. Exp. Ther. 315 (2005) 971
3. Krause D.S., and Van Etten R.A. N. Engl. J. Med. 353 (2005) 172
4. Hubbard S.R., and Till J.H. Annu. Rev. Biochem. 69 (2000) 373
5. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S., Cornelius L.A., Das J., Doweyko A.M., Fairchild C., Hunt J.T., Inigo I., Johnston K., Kamath A., Kan D., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G.L., Schmidt R.J., Tokarski J., Wen M.L., Wityak J., and Borzilleri R.M. J. Med. Chem. 47 (2004) 6658
6. Ramirez P., and DiPersio J.F. Oncologist 13 (2008) 424
7. Xia W., Mullin R.J., Keith B.R., Liu L.H., Ma H., Rusnak D.W., Owens G., Alligood K.J., and Spector N.L. Oncogene 21 (2002) 6255
8. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S.D., Stein S., and Cameron D. N. Engl. J. Med. 355 (2006) 2733
9. Hsieh S., Tobien T., Koch K., and Dunn J. Rapid Commun. Mass Spectrom. 18 (2004) 285
10. Bai F., Freeman III B.B., Fraga C.H., Fouladi M., and Stewart C.F. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 831 (2006) 169
11. Wang L., Christopher L.J., Cui D., Li W., Iyer R., Humphreys W.G., and Zhang D. Drug Metab. Dispos. 36 (2008) 1828
12. Hiwase D.K., Saunders V., Hewett D., Frede A., Zrim S., Dang P., Eadie L., To L.B., Melo J., Kumar S., Hughes T.P., and White D.L. Clin. Cancer Res. 14 (2008) 3881
13. Kamath A.V., Wang J., Lee F.Y., and Marathe P.H. Cancer Chemother. Pharmacol. 61 (2008) 365
14. De Francia S., D'Avolio A., De Martino F., Pirro E., Baietto L., Siccardi M., Simiele M., Racca S., Saglio G., Di Carlo F., and Di Perri G. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 877 (2009) 1721
15. Hsieh Y., Galviz G., Zhou Q., and Duncan C. Rapid Commun. Mass Spectrom. 23 (2009) 1364
16. Haouala A., Zanolari B., Rochat B., Montemurro M., Zaman K., Duchosal M.A., Ris H.B., Leyvraz S., Widmer N., and Decosterd L.A. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2009)
17. O'Connor R. Anticancer Res. 27 (2007) 1267
18. O'Connor R., Clynes M., Dowling P., O'Donovan N., and O'Driscoll L. Exp. Opin. Drug Metab. Toxicol. 3 (2007) 805
19. Ozvegy-Laczka C., Cserepes J., Elkind N.B., and Sarkadi B. Drug Resist. Update 8 (2005) 15
20. Polli J.W., Humphreys J.E., Harmon K.A., Castellino S., O'Mara M.J., Olson K.L., John-Williams L.S., Koch K.M., and Serabjit-Singh C.J. Drug Metab. Dispos. 36 (2008) 695
21. Collins D.M., O'Connor R., O'Donovan N., Clynes M., and Crown J. Ann. Oncol. 17 (2006) 57
22. McBride S., Meleady P., Baird A., Dinsdale D., and Clynes M. Tumour Biol. 19 (1998) 88
23. Duffy C.P., Elliott C.J., O'Connor R.A., Heenan M.M., Coyle S., Cleary I.M., Kavanagh K., Verhaegen S., O'Loughlin C.M., NicAmhlaoibh R., and Clynes M. Eur. J. Cancer 34 (1998) 1250
24. Jemal M. Biomed. Chromatogr. 14 (2000) 422
25. Oostendorp R.L., Beijnen J.H., Schellens J.H., and Tellingen O. Biomed. Chromatogr. 21 (2007) 747
26. Zirrolli J.A., Bradshaw E.L., Long M.E., and Gustafson D.L. J. Pharm. Biomed. Anal. 39 (2005) 705
27. Ermer J. J. Pharm. Biomed. Anal. 24 (2001) 755
28. Shah V.P., Midha K.K., Dighe S., McGilveray I.J., Skelly J.P., Yacobi A., Layloff T., Viswanathan C.T., Cook C.E., McDowall R.D., Pittman K.A., and Spector S. J. Pharm. Sci. 81 (1992) 309